Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Trial Profile

A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2019

At a glance

  • Drugs Irinotecan (Primary) ; Temozolomide (Primary) ; Temozolomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Vincristine
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2018 Planned number of patients changed from 83 to 93.
    • 06 Aug 2018 Planned End Date changed from 1 May 2019 to 1 May 2020.
    • 06 Aug 2018 Planned primary completion date changed from 1 May 2019 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top